Skip to Content

Bio-Path Holdings Inc BPTH

Morningstar Rating
$5.80 −0.05 (0.85%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BPTH is trading at a 69% discount.
Price
$5.83
Fair Value
$87.68
Uncertainty
Extreme
1-Star Price
$232.22
5-Star Price
$3.19
Economic Moat
Qqt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPTH is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.85
Day Range
$5.556.12
52-Week Range
$5.5544.80
Bid/Ask
$5.58 / $6.48
Market Cap
$3.58 Mil
Volume/Avg
10,613 / 6,954

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
10

Valuation

Metric
BPTH
Price/Earnings (Normalized)
Price/Book Value
2.06
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BPTH
Quick Ratio
1.73
Current Ratio
3.54
Interest Coverage
Quick Ratio
BPTH

Profitability

Metric
BPTH
Return on Assets (Normalized)
−139.17%
Return on Equity (Normalized)
−169.08%
Return on Invested Capital (Normalized)
−166.20%
Return on Assets
BPTH
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSpntx$546.8 Bil
VRTX
Vertex Pharmaceuticals IncSjdsmk$112.0 Bil
REGN
Regeneron Pharmaceuticals IncDxkgw$108.6 Bil
MRNA
Moderna IncTnrg$35.9 Bil
ARGX
argenx SE ADRFxfw$24.1 Bil
BNTX
BioNTech SE ADRNch$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncPxswvrv$20.0 Bil
BMRN
Biomarin Pharmaceutical IncVlyzjy$17.0 Bil
RPRX
Royalty Pharma PLC Class AJzrsph$14.0 Bil
INCY
Incyte CorpFkypmf$13.6 Bil

Sponsor Center